Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
Abstract
Purpose The purpose of this study was to evaluate the impact of postmastectomy radiotherapy (PMRT) on loco-regional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) in pT1-2N1 patients treated with taxane-based chemotherapy. Materials and Methods We retrospectively reviewed the medical data of pathological N1 patients who were treated with modified radical mastectomy and adjuvant taxane-based chemotherapy in 12 hospitals between January 2006 and December 2010. Results We identified 714 consecutive patients. The median follow-up duration was 69 months (range, 1 to 114 months) and the 5-year LRRFS, DFS, and OS rates were 97%, 94%, and 98%, respectively, in patients who received PMRT (PMRT [+]). The corresponding figures were 96%, 90%, and 96%, respectively, in patients who did not receive PMRT (PMRT [–]). PMRT had no significant impact on survival. Upon multivariable analysis, only the histological grade (HG) was statistically significant as a prognostic factor for LRRFS and DFS. In a subgroup analysis of HG 3 patients, PMRT (+) showed better DFS (p=0.081). Conclusion PMRT had no significant impact on LRRFS, DFS, or OS in pT1-2N1 patients treated with taxane- based chemotherapy. PMRT showed a marginal benefit for DFS in HG 3 patients. Randomized studies are needed to confirm the benefit of PMRT in high risk patients, such as those with HG 3.
참고문헌 (19)
- National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology: breast cancer, version 2" (2016), National Comprehensive Cancer Network
- Ragaz J, "Locoregional radiation therapy in patients with highrisk breast cancer receiving adjuvant chemotherapy : 20-year results of the British Columbia randomized trial", J Natl Cancer Inst, 97, pp.116~126 (2005)
- Overgaard M, "Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials", Radiother Oncol, 82, pp.247~253 (2007)
- EBCTCG(Early Breast Cancer Trialists' Collaborative Group), "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality : metaanalysis of individual patient data for 8135 women in 22 randomised trials", Lancet, 383, pp.2127~2135 (2014)
- Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- De Laurentiis M, "Taxane-based combinations as adjuvant chemotherapy of early breast cancer : a meta-analysis of randomized trials", J Clin Oncol, 26, pp.44~53 (2008)
- Mackey JR, "Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer : 10-year follow-up of the phase 3 randomised BCIRG 001 trial", Lancet Oncol, 14, pp.72~80 (2013)
- Mamounas EP, "Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28", J Clin Oncol, 23, pp.3686~3696 (2005)
- Sartor CI, "Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer : cancer and leukemia group B 9344", J Clin Oncol, 23, pp.30~40 (2005)
- Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Comparisons between different polychemotherapy regimens for early breast cancer : meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials", Lancet, 379, pp.432~444 (2012)
- McBride A, "Locoregional recurrence risk for patients with T1, 2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment", Int J Radiat Oncol Biol Phys, 89, pp.392~398 (2014)
- Chang JS, "Do recent advances in diagnostic and therapeutic procedures negate the benefit of postmastectomy radiotherapy in N1 patients with a low risk of locoregional recurrence?", Medicine (Baltimore), 94, pp.e1259~ (2015)
- Taghian A, "Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy : results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials", J Clin Oncol, 22, pp.4247~4254 (2004)
- Yu JI, "Determining which patients require irradiation of the supraclavicular nodal area after surgery for N1 breast cancer", Int J Radiat Oncol Biol Phys, 78, pp.1135~1141 (2010)
- Ge Wen, "Predictive Value of Molecular Subtyping for Locoregional Recurrence in Early-Stage Breast Cancer with N1 without Postmastectomy Radiotherapy", Journal of Breast Cancer, 19(2), pp.176~184 (2016), 한국유방암학회
- Moo TA, "Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes", Ann Surg Oncol, 21, pp.1569~1574 (2014)
- Lai SF, "Locoregional recurrence risk for postmastectomy breast cancer patients with T1-2 and one to three positive lymph nodes receiving modern systemic treatment without radiotherapy", Ann Surg Oncol, 23, pp.3860~3869 (2016)
- Yu JI, "Prognostic modeling in pathologic N1 breast cancer without elective nodal irradiation after current standard systemic management", Clin Breast Cancer, 15, pp.e197~e204 (2015)
- Tendulkar RD, "Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy", Int J Radiat Oncol Biol Phys, 83, pp.e577~581 (2012)